文献速递银屑病与炎症性皮肤病

生物制剂对中重度斑块状银屑病患者抑郁与焦虑症状影响的系统综述与网络Meta分析

Effect of Biologic Therapy on Depression and Anxiety Symptoms in Patients With Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis.
PubMed 文献 · Br J Dermatol · 2026-10-03

该系统综述与网络Meta分析纳入8项研究共4319例中重度斑块状银屑病患者,评估生物制剂对抑郁和焦虑症状的影响。机制层面,所有生物制剂类别均显著优于安慰剂;抑郁以IL-12/23抑制剂效应最大(SMD=0.677,95%CI:0.473,0.881),焦虑以IL-23和IL-12/23抑制剂相似(SMD均为0.457)。心理改善通常伴随皮损改善,但两者非严格成比例。

要点

  • 生物制剂短期可改善中重度银屑病患者的抑郁和焦虑症状。
  • 抑郁改善以IL-12/23抑制剂估计值最大,焦虑以IL-23和IL-12/23抑制剂相似。
  • 心理改善通常伴随皮损改善,但两者不严格成比例。

核心结论

  • 生物制剂治疗与中重度银屑病患者短期抑郁和焦虑症状改善相关,支持心理健康作为整体治疗获益的相关组成部分。
  • 心理改善通常伴随皮损应答,但不同机制和单个药物间的比较差异需更大规模、更长周期的随机研究确认。

研究设计与样本

  • 系统综述与网络Meta分析,检索PubMed、Web of Science、Embase和Cochrane对照试验中心注册库至2026年1月28日。
  • 纳入中重度银屑病成人患者的随机对照试验和前瞻性比较队列研究,共8项研究、4319例患者。
  • 采用频率学派随机效应网络Meta分析,在机制和药物层面进行,并评估网络不一致性、敏感性分析、偏倚风险和证据确定性。

主要发现

  • 机制层面,所有生物制剂类别 versus 安慰剂均显著改善抑郁和焦虑症状。
  • 抑郁方面,IL-12/23抑制剂的估计值最大(SMD=0.677,95%CI:0.473,0.881)。
  • 焦虑方面,IL-23抑制剂(SMD=0.457,95%CI:0.304,0.610)和IL-12/23抑制剂(SMD=0.457,95%CI:0.335,0.579)估计值相似。
  • 药物层面,多种药物显示获益,但因网络稀疏且证据确定性从高到低不等,排名不确定。
  • 研究内和探索性比较水平分析提示心理改善通常伴随皮损改善,但两者不严格成比例。

关键数值与推荐

  • 纳入标准:中重度斑块状银屑病成人患者的随机对照试验和前瞻性比较队列研究。
  • 抑郁结局:IL-12/23抑制剂SMD=0.677(95%CI:0.473,0.881)。
  • 焦虑结局:IL-23抑制剂SMD=0.457(95%CI:0.304,0.610);IL-12/23抑制剂SMD=0.457(95%CI:0.335,0.579)。

临床怎么用

  • 临床可考虑将生物制剂治疗视为同时改善中重度银屑病患者短期抑郁和焦虑症状的潜在获益。
  • 心理改善通常随皮损改善出现,但不应假设两者严格成比例,需关注患者心理症状变化。
  • 不同生物制剂机制和单个药物间的心理疗效差异尚不确定,药物选择应综合评估。

局限性

  • 纳入研究数量较少(8项),网络稀疏,药物层面排名不确定。
  • 证据确定性从高到低不等,部分比较可靠性有限。
  • 心理改善与皮损改善的关联来自研究内和探索性分析,需进一步验证。
  • 结论主要基于短期数据,长期心理获益需更长周期研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Various biologics are already widely used to treat patients with moderate-to-severe psoriasis, but there is currently a lack of comparative data on their effectiveness in improving symptoms of anxiety and depression. OBJECTIVE: To evaluate and compare the effects of biologic therapies on depression and anxiety symptoms in patients with psoriasis using a systematic review and network meta-analysis. METHODS: We searched PubMed, Web of Science, Embase, and the Cochrane Central Register of Controlled Trials from inception to January 28, 2026. Randomized controlled trials and prospective comparative cohort studies in adults with moderate-to-severe psoriasis were included. Frequentist random-effects NMA was conducted at mechanism and drug levels, with network incoherence, sensitivity analyses, risk of bias, and certainty of evidence assessed. Skin-response associations and clinically interpretable psychological outcomes were additionally summarized. RESULTS: Eight studies involving 4,319 patients were included. At the mechanism level, all biologic classes significantly improved depression and anxiety symptoms versus placebo. For depression, IL-12/23 inhibitors had the largest estimate [standardized mean difference (SMD) = 0.677, 95% confidence interval (CI): 0.473, 0.881]; for anxiety, IL-23 (SMD=0.457, 95%CI: 0.304, 0.610) and IL-12/23 (SMD=0.457, 95%CI: 0.335, 0.579) inhibitors had similar estimates. At the drug level, several agents showed benefit, but rankings were uncertain because networks were sparse and certainty ranged from high to low. Within-study and exploratory comparison-level analyses indicated that psychological improvement generally accompanied skin improvement, yet the two were not strictly proportional. CONCLUSION: Biologic therapy was associated with short-term improvement in depressive and anxiety symptoms in moderate-to-severe psoriasis, supporting mental health as a relevant component of overall treatment benefit. Psychological improvement generally accompanied skin response, while comparative differences across mechanisms and individual agents require confirmation in larger and longer randomized studies.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Tang J, Wen Y, Chen K, et al. Effect of Biologic Therapy on Depression and Anxiety Symptoms in Patients With Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis. Br J Dermatol. 2026. PMID: 42828417. doi:10.1093/bjd/ljag435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。